Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations

Pharmacology Research & Perspectives
Joaquim F MonteiroPaula Fresco

Abstract

Vancomycin is a fundamental antibiotic in the management of severe Gram-positive infections. Inappropriate vancomycin dosing is associated with therapeutic failure, bacterial resistance and toxicity. Therapeutic drug monitoring (TDM) is acknowledged as an important part of the vancomycin therapy management, at least in specific patient subpopulations, but implementation in clinical practice has been difficult because there are no consensus and agglutinator documents. The aims of the present work are to present an overview of the current knowledge on vancomycin TDM and population pharmacokinetic (PPK) models relevant to specific patient subpopulations. Based on three published international guidelines (American, Japanese and Chinese) on vancomycin TDM and a bibliographic review on available PPK models for vancomycin in distinct subpopulations, an analysis of evidence was carried out and the current knowledge on this topic was summarized. The results of this work can be useful to redirect research efforts to address the detected knowledge gaps. Currently, TDM of vancomycin presents a moderate level of evidence and practical recommendations with great robustness in neonates, pediatric and patients with renal impairment. However, i...Continue Reading

References

Jun 1, 1990·Antimicrobial Agents and Chemotherapy·A K HurstE C Harrison
Jun 1, 1995·Therapeutic Drug Monitoring·K A RodvoldJ R Gross
Feb 18, 1998·Clinical Pharmacology and Therapeutics·F Schaedeli, D E Uehlinger
Oct 18, 2000·Therapeutic Drug Monitoring·R E WrishkoD Hamilton
Sep 11, 2001·Journal of Clinical Pharmacology·E V CapparelliJ D Connor
Dec 14, 2006·Intensive Care Medicine·Maria del Mar Fernández de Gatta GarciaAmparo Sánchez Navarro
Feb 13, 2007·Journal of Clinical Pathology·R K CrowleyE G Smyth
Apr 26, 2008·BMJ : British Medical Journal·Gordon H GuyattUNKNOWN GRADE Working Group
Jul 11, 2008·Current Opinion in Critical Care·Jason A RobertsJordi Rello
Dec 25, 2008·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Michael RybakDonald P Levine
Mar 21, 2009·The Journal of Antimicrobial Chemotherapy·A H ThomsonA M Lovering
Oct 8, 2009·Therapeutic Drug Monitoring·Christopher J PayneAlexander R Binning
Oct 31, 2009·Burns : Journal of the International Society for Burn Injuries·Michael DoltonAndrew J McLachlan
Dec 17, 2009·Scandinavian Journal of Infectious Diseases·Matthieu RoustitPatricia Pavese
Nov 3, 2010·British Journal of Clinical Pharmacology·María-Remedios Marqués-MiñanaJosé-Esteban Peris
Nov 16, 2010·International Journal of Antimicrobial Agents·A JeurissenR Rutsaert
Mar 8, 2011·Archives of Disease in Childhood. Fetal and Neonatal Edition·C OudinN Simon
Mar 16, 2011·Antimicrobial Agents and Chemotherapy·Jason A RobertsJeffrey Lipman
Mar 25, 2011·International Journal of Clinical Pharmacology and Therapeutics·E F BadranY M Irshaid
Apr 28, 2011·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Anthony JarkowskiMeir Wetzler
May 5, 2011·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Belén Montañés PaulsVicente G Casabó Alós
Nov 19, 2011·Journal of Anaesthesiology, Clinical Pharmacology·Said Abuhasna, Amer H Al Jundi
Feb 15, 2012·International Journal of Clinical Pharmacy·Maria SwartlingB Joseph Guglielmo
May 1, 2010·The Canadian Journal of Hospital Pharmacy·Lyndsay M van de VijselMichelle Hladunewich
Aug 11, 2012·Journal of Burn Care & Research : Official Publication of the American Burn Association·Kevin S AkersClinton K Murray
Aug 16, 2012·Clinics·Gian Maria Pacifici, Karel Allegaert
Aug 29, 2012·The Pediatric Infectious Disease Journal·Brady S Moffett, Morven S Edwards
Nov 10, 2012·Seminars in Fetal & Neonatal Medicine·Evelyne Jacqz-AigrainJohn N van den Anker
Nov 29, 2012·Internal Medicine Journal·M L AventD L Paterson
Dec 21, 2012·Archives of Disease in Childhood·Wei ZhaoEvelyne Jacqz-Aigrain
Dec 29, 2012·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·F M BuyleD Vogelaers
Mar 6, 2013·International Journal of Clinical Pharmacology and Therapeutics·Chenhui DengWei Lu
May 16, 2013·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Kazuaki MatsumotoToshimi Kimura
Jun 27, 2013·Pharmacotherapy·Daniel E HebleDavid A Hunstad
Jul 5, 2013·Pharmacotherapy·Chris StockmannMichael G Spigarelli
Jan 1, 2014·The Pediatric Infectious Disease Journal·Amanda GweeNigel Curtis
Jan 24, 2014·Therapeutic Drug Monitoring·Jennifer LeEdmund V Capparelli

❮ Previous
Next ❯

Citations

Jun 7, 2019·British Journal of Clinical Pharmacology·Robin Ferner, Jeffrey Aronson
Jul 16, 2019·Expert Opinion on Drug Safety·Nicola Principi, Susanna Esposito
Jan 21, 2020·Pharmacotherapy·Anne M MasichMathangi Gopalakrishnan
Jan 13, 2021·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Samareh ArjangpourSeied Asadollah Mousavi
Jun 23, 2021·European Journal of Drug Metabolism and Pharmacokinetics·Kannan SridharanMwila Mulubwa
Sep 24, 2020·Journal of the American Chemical Society·Julien C VantouroutPhil S Baran
Jul 2, 2021·Pediatrics International : Official Journal of the Japan Pediatric Society·Aiju EndoTakehisa Hanawa

❮ Previous
Next ❯

Software Mentioned

Ovid

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.